- Conditions
- Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
- Interventions
- DB-OTO
- Genetic
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Diego, California • Jacksonville, Florida + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C
- Interventions
- Eltrombopag, Antiviral therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- San Diego, California • New Haven, Connecticut • Honolulu, Hawaii + 3 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin
- Drug
- Lead sponsor
- Eccogene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Healthy Volunteer
- Interventions
- Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Healthy Volunteers
- Interventions
- AZD9291
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
- Interventions
- BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7), Monovalent BNT162b2 (B.1.617.2), Monovalent BNT162b2 (B.1.1.529.1), Observational
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 14
- States / cities
- Long Beach, California • San Diego, California • Milford, Connecticut + 10 more
- Conditions
- Type 1 Diabetes
- Interventions
- Autologous UCB, Omega 3 FA, Vitamin D
- Biological · Dietary Supplement
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- CX-072, ipilimumab, vemurafenib
- Drug
- Lead sponsor
- CytomX Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 10 more
- Conditions
- HIV-1 Infection, HCV Infection
- Interventions
- E/C/F/TAF, F/R/TAF, LDV/SOF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
- Conditions
- Lung Cancer Metastatic, EGFR Gene Mutation
- Interventions
- Osimertinib, Alisertib
- Drug
- Lead sponsor
- Collin Blakely
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Advanced Solid Tumors Cancer, MSI-H Cancer
- Interventions
- NDI-219216
- Drug
- Lead sponsor
- Nimbus Wadjet, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Chicago, Illinois • Louisville, Kentucky + 8 more
- Conditions
- Sleep Apnea Syndromes, Inflammation
- Interventions
- Weight Loss Program, CPAP therapy
- Behavioral · Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
- Interventions
- SEA-TGT, sasanlimab, brentuximab vedotin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more
- Conditions
- Community-acquired Infection
- Interventions
- GSK2251052 750 mg, GSK2251052 1500 mg, GSK2251052 1500 mg BID, GSK2251052 2250 mg, GSK2251052 3000 mg, GSK2251052 0.9% saline
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Solid Tumors
- Interventions
- ARQ 761, ARQ 761 Weekly Administration, Bi-Weekly Administration of ARQ 761, Two Consecutive Weeks Administration of ARQ 761 with one week of rest
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy
- Interventions
- Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Diabetic Foot Ulcer
- Interventions
- AMNIOEXCEL Plus Amniotic Membrane, A Marketed Comparator, Standard of Care
- Other · Device
- Lead sponsor
- Integra LifeSciences Corporation
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Fresno, California • Los Angeles, California • Gainesville, Georgia + 3 more
- Conditions
- B-Cell Chronic Lymphocytic Leukemia (B-CLL)
- Interventions
- Alemtuzumab
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 7
- States / cities
- La Jolla, California • La Verne, California • Aurora, Colorado + 4 more
- Conditions
- Advanced Solid Tumours
- Interventions
- AZD1775, MEDI4736
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
- Conditions
- Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
- Interventions
- Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Ibrutinib, Methotrexate, Rituximab, Venetoclax, Vincristine Sulfate
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
- Interventions
- Dexamethasone, Vincristine, Daunorubicin, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Methotrexate, Cytarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 5
- States / cities
- San Diego, California • Baton Rouge, Louisiana • Charlotte, North Carolina + 2 more
- Conditions
- Healthy Participants
- Interventions
- TAK-994, TAK-994 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Glendale, California • Salt Lake City, Utah
- Conditions
- Glioblastoma
- Interventions
- WSD0628
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota